Abstract:BackgroundAnti-aquaporin-4 antibody (AQP4-IgG) is a diagnostic marker of neuromyelitis optica spectrum disorder (NMOSD), but the relationship of different AQP4-IgG serostatus with clinical manifestations and recurrence of disease is still uncertain.ObjectiveWe attempted to observe the changes of AQP4-IgG serostatus and the differences of corresponding clinical manifestations between AQP4-IgG-positive (AQP4-IgG+) and AQP4-IgG-negative (AQP4-IgG−) patients during 36-month follow-up, and to explore the significance of AQP4-IgG serostatus in the pathogenesis of NMOSD.MethodsThe AQP4-IgG serostatus in eighty-four NMOSD patients during 36 months were re-checked regularly every 6 months in stable phase of the disease, and an additional AQP4-IgG test was performed when the disease relapsed. The clinical data were collected, including gender, age, clinical symptoms and signs, location and length of affected spinal cord segments, expanded disability status scale (EDSS), course of disease, annual recurrence rate (ARR), concomitant connective tissue disease (CTD) and other autoimmune antibodies. According to the change of AQP4-IgG serostatus during 36 months, the enrolled patients were divided into the various groups: with AQP4-IgG+ at the first diagnosis; with AQP4-IgG− at the first diagnosis; with persistent AQP4-IgG+; with persistent AQP4-IgG−; with conversion to AQP4-IgG−. The clinical characteristics of NMOSD patients among different groups were compared.ResultsEighty-four NMOSD patients (12 males and 72 females) were included in this study. For the patients with AQP4-IgG+ at the first diagnosis (60 patients, 71.4%), there were 29 patients (48.3%) continuously positive; 31 cases (51.7%) turned positive to negative while 9 cases (29.0%) turned positive again in which 7 cases (77.8%) coincided with recurrence. The re-positive change of AQP4-IgG was significantly correlated with the recurrence of the disease (P < 0.05); for the patients with AQP4-IgG− at the first diagnosis (24 patients, 28.6%), 19 patients (79.2%) remained negative, and 5 patients (20.8%) turned negative to positive in which 1 patient (20.0%) had a relapse. This conversion of AQP4-IgG serostatus had no significant correlation with the recurrence of the disease (P >0.05). There was no significant difference in clinical manifestations between the AQP4-IgG+ and AQP4-IgG− group at the diagnosis, or between the persistent AQP4-IgG+ and persistent AQP4-IgG− group during thirty-six months (P > 0.05). The patients with persistent AQP4-IgG+ was more likely to accompany with other antibodies than those with conversion to AQP4-IgG− (P < 0.05), while no significant differences were found in the gross clinical characteristics. (P > 0.05).ConclusionsAQP4-IgG serostatus can fluctuate in the different phase of NMOSD. There is no significant difference in clinical characteristics between AQP4-IgG+ and AQP4-IgG− patients. The conversion of AQP4-IgG+ to AQP4-IgG− may not be an appropriate target for treatment, but patients who are AQP4-IgG+ turn positive again after conversion to negative need to be vigilant for the recurrence of the disease.

Analysis of clinical features of five multiple sclerosis patients with positive serum aquaporin 4 antibody

Clinical features of Chinese patients with multiple sclerosis with aquaporin-4 antibodies in cerebrospinal fluid but not serum.

Serum Aquaporin 4-Immunoglobulin G Titer and Neuromyelitis Optica Spectrum Disorder Activity and Severity: A Systematic Review and Meta-Analysis

A clinical analysis of patients with AQP4-IgG and MOG-IgG seropositive.

Significance of oligoclonal bands and aquaporin-4 antibody in diagnosis of multiple sclerosis

Retrospective analysis of the diagnosis of patients with positive aquaporin-4 antibody

Factors influencing the cerebrospinal fluid antibodies to aquaporin-4: a study of 87 patients with neuromyelitis optica spectrum disorder

Aquaporin 4 Antibodies in the Cerebrospinal Fluid Are Helpful in Diagnosing Chinese Patients with Neuromyelitis Optica.

Anti-aquaporin-4 Antibody in Chinese Patients with Central Nervous System Inflammatory Demyelinating Disorders

Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder

Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis

Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus

Serum-positive and -negative AQP4 antibody NMO in Chinese patients.

[Detection of anti-aquaporin 4 antibody in neuromyelitis optical].

The Clinical Characteristics of AQP4 Antibody Positive NMO/SD in a Large Cohort of Chinese Han Patients.

Association of aquaporin-4 polymorphisms with multiple sclerosis and neuromyelitis optica

Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder

Detection of Aquaporins-4:Methods Comparison and Clinical Significance for the Diagnosis of Neuromyelitis Optica

Preliminary study on the association of AQP4 promoter polymorphism with anti-aquaporin-4 antibody positivity in southern Han Chinese patients with idiopathic demyelinating disorders of central nervous system.

Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity.

Comparison of Clinical Characteristics and Prognoses in Patients with Different AQP4-Ab and MOG-Ab Serostatus with Neuromyelitis Optica Spectrum Disorders